Post-Transplant Cyclophosphamide in Combination with Abatacept and Bortezomib for GVHD Prophylaxis: Interim Results of the ABC Phase I–IIb Trial

Key Points

• Cyclophosphamide combined with abatacept and bortezomib shows promising results for GVHD prevention.
• The combination therapy reduced GVHD incidents to 20% within the first six months in participants.
• Intervention was assessed in a Phase I–IIb trial focusing on GVHD prophylaxis post-transplant.
• Findings highlight the potential of this approach in improving transplant outcomes; further evaluation needed.